Tango Therapeutics is conducting an at-the-market offering of up to $400M (last sale $27.07)/share

Filed August 11, 2026 · ~1 min read

Key Changes

• high

  At-the-market offering of up to $400M of common stock at market prices; at the illustrative price of $27.07/share (August 7, 2026 close), the company would issue 14.8M shares for net proceeds of $391M.

  The Offering verify on EDGAR →
• high

  Implied post-offering market capitalization of $5.0B (183.2M shares outstanding at $27.07/share).

  The Offering verify on EDGAR →
• medium

  Net proceeds of $391M will fund general corporate purposes including working capital, operating expenses, R&D, manufacturing, and clinical trials; management retains broad discretion over allocation.

  Use of Proceeds verify on EDGAR →